LONDON (Alliance News) - Scancell Holdings PLC on Wednesday said a review published in the scientific journal Autophagy supports the potential of its Moditope platform.
The review, titled 'Autophagy, citrullination and cancer', discusses the concept that citrullinated peptides produced during autophagy offer attractive vaccine targets for cancer therapy, Scancell said.
The Moditope platform uses this mechanism to stimulate the production of highly active CD4+ T cells that overcome self-tolerance and destroy tumour cells.
"The interplay between autophagy, citrullination and cancer support the rationale behind our Moditope platform technology. Moditope has a unique mechanism of action that overcomes the immune suppression induced by tumour cells, allowing T cells to seek out and kill tumours that would otherwise be hidden from the immune system. We believe this platform has the potential to develop a new class of immuno-oncology therapeutics and look forward to progressing our first vaccine into the clinic as soon as possible," said Chief Scientific Officer Lindy Durrant in a statement.
Shares in Scancell were up 1.5% at 17.00 pence Wednesday.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)